Insights

Regulatory Intelligence
and Research

News, thought leadership, and regulatory intelligence from the THESYL team - covering East African pharmaceutical regulation, clinical research, and pharmacovigilance

First Approval 14 March 2026

First Rwanda FDA Approval Achieved: USOPENTIN 300 Becomes the First Product Registered Under THESYL Management

On 14 March 2026, THESYL reached the most significant milestone in its history: the Rwanda FDA granted marketing authorization for USOPENTIN 300, registered under the National Full Assessment procedure - the authority's most rigorous review pathway.

On 14 March 2026, THESYL reached the most significant milestone in its short history: the Rwanda Food and Drugs Authority granted marketing authorization for USOPENTIN 300, making it the first product to receive full Rwanda FDA registration under THESYL's regulatory management.

Registration No.: RWANDA-FDA25/HM/0010/0031 · Manufacturer: Hikal Limited, India · MAH: USOPHARMA Ltd · Valid: 14 March 2026 - 13 March 2031

The registration of USOPENTIN 300 demonstrates that THESYL's model - combining global regulatory standards with deep in-country Rwanda FDA expertise - delivers concrete, measurable results for its clients.

Milestone 17 June 2025

Milestone: THESYL Reaches 31 Dossiers Submitted to Rwanda FDA on Behalf of USOPHARMA Ltd

Eleven months after filing its first submission, THESYL reached a significant operational milestone: the 31st product dossier submitted to Rwanda FDA.

The 31 submissions span conventional small-molecule medicines and biologicals/biosimilars from multiple manufacturers across therapeutic areas.

Important: all submissions are made on behalf of USOPHARMA Ltd as MAH; THESYL acts as regulatory affairs partner.

Company News 2 July 2024

THESYL Establishes Rwanda Operations with First Client Mandate: A 50-Product Registration Programme with USOPHARMA Ltd

In July 2024, THESYL AB formally established its operational presence in Rwanda, beginning a 50-product registration programme on behalf of USOPHARMA Ltd.

The programme covers conventional medicines and biologicals/biosimilars across multiple therapeutic areas and manufacturers.

"We have been collaborating with THESYL on drug market registration projects, and their expertise has been instrumental in navigating every step."

Placide Sophroni UWINGENEYE, Managing Director, USOPHARMA Ltd
Regulatory Affairs 8 min read

What Pharmaceutical Manufacturers Get Wrong About Rwanda FDA Registration

Rwanda's regulatory authority has become one of Africa's most capable, yet international manufacturers consistently make avoidable mistakes.

The assumption that leads to most delays

Most delays begin with incorrect assumptions that Rwanda FDA is either informal or equivalent to a simplified Western process.

The decision framework

  • Recognised SRA approval: Abridged Procedure
  • Eligible African reference market: Assess MRP eligibility
  • No SRA anchor: National Full Assessment
Clinical Research 8 min read

The NCD Research Gap in Africa: Why Rwanda Is an Underused Clinical Trial Destination

Africa carries a major NCD burden yet remains underrepresented in Phase II-IV global research activity.

Rwanda FDA's ML3 status, operational stability, and site concentration make Rwanda a practical trial destination for high-quality execution.

Regulatory Policy 7 min read

The African Medicines Agency: What It Means for Pharmaceutical Regulation Across Africa

The AMA's emergence signals the most significant structural shift in continental regulation in a generation.

White Paper Clinical Research

Advancing Clinical Trials in Africa: Opportunities and Challenges

An overview of Africa's emerging role as a clinical trial destination and the practical realities sponsors and CROs face.

Download
White Paper Pharmacovigilance

Pharmacovigilance in Africa: Strengthening Safe Use of Medicines

An examination of PV infrastructure, regulatory frameworks, and post-marketing safety practice across Africa.

Download
Case Study

Building Rwanda's Most Ambitious Private Registration Programme

THESYL and USOPHARMA Ltd · Active since July 2024

Client

USOPHARMA Ltd, Kigali, Rwanda

Engagement commenced

2 July 2024

Programme scope

50-product Rwanda FDA registration

Submissions to date

31 dossiers (as of 17 June 2025)